Oliver Sartor MDDirector of the Radiopharmaceutical Trials, Chief of the Genitourinary Cancer Malignancy Group, Mayo Clinic, Rochester, Minnesota
Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval (Quadramet, Xofigo, Pluvicto, and Jevtana). He has lectured widely, and at last count has given invited lectures in 33 countries.
He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel, is past Editor-in-Chief of the peer-reviewed journal Clinical Genitourinary Cancer, and is the Medical Oncology Chair of the GU committee of NRG, a national cancer research group. He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology).
CONSULTANT: Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen, Merck, Moyvant, Myriad, Noria Therapeutics, Inc., Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, Theragnostics.
Grant/Research Support: Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, Tenebio.
Recent Contributions to PracticeUpdate:
- 2023 Top Story in Prostate Cancer: PARP Inhibition Moves Forward
- Digital Pathology–Based Multimodal AI-Derived Model in Localized Metastatic Prostate Cancer
- Refining Risk Stratification in Patients Undergoing Radiotherapy and Long-Term ADT for High-Risk/Locally Advanced Prostate Cancer
- Pembrolizumab Plus Enzalutamide and ADT for Patient With mHSPC
- AMG 509 (Xaluritamig) in Patients With mCRPC
- RADICALS RT: Timing of Adjuvant Radiotherapy Following Radical Prostatectomy
- ENZA-p: Enzalutamide and 177Lu–PSMA-617 in Patients With Poor-Risk mCRPC
- PSMAfore: 177Lu–PSMA-617 in Taxane-Naïve Patients With Metastatic Castration-Resistant Prostate Cancer
- Addition of Docetaxel to Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer
- 2022 Top Story in Advanced Prostate Cancer: Efficacy of Abiraterone and Prednisolone Alone or With Enzalutamide in High-Risk Nonmetastatic Prostate Cancer